At ArgoBio, we build therapeutics-based biotech companies using breakthrough science.
We have raised 50 M€ funding to launch and support disruptive translational research projects up to company creation and Series A financing. Our team is located in France and in the UK and acting across Europe and beyond.
Argobio also provides operational excellence to early-stage projects. We allocate a team of experienced scientists and entrepreneurs to mature the projects. We are closely collaborating with the academic research team for the development of therapeutics. The new companies will be created during the incubation phase.
Activities covered by Argobio include translational work at the academic lab by the principal investigator and at CROs for preclinical testing, tox, manufacturing…
Argobio is sponsored by 5 complementary investors.
Argobio has built a pipeline of projects
reflecting the diversity of therapeutic indications
and modalities interest.
Argobio has assembled an experienced team
with track-record in science and entreneurship.